Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the 'treat-all' strategy.


Journal

PLOS global public health
ISSN: 2767-3375
Titre abrégé: PLOS Glob Public Health
Pays: United States
ID NLM: 9918283779606676

Informations de publication

Date de publication:
2022
Historique:
received: 12 06 2021
accepted: 13 02 2022
entrez: 24 3 2023
pubmed: 25 3 2023
medline: 25 3 2023
Statut: epublish

Résumé

The retention of patients in care is a key pillar of the continuum of HIV care. It has been suggested that the implementation of a "treat-all" strategy may favor attrition (death or lost to follow-up, as opposed to retention), specifically in the subgroup of asymptomatic people living with HIV (PLWH) with high CD4 counts. Attrition in HIV care could mitigate the success of universal antiretroviral therapy (ART) in resource-limited settings. We performed a retrospective study of PLWH at least 15 years old initiating ART in 85 HIV care centers in Kinshasa, Democratic Republic of Congo (DRC), between 2010 and 2019, with the objective of measuring attrition and to define factors associated with it. Sociodemographic and clinical characteristics recorded at ART initiation included sex, age, weight, height, WHO HIV stage, pregnancy, baseline CD4 cell count, start date of ART, and baseline and last ART regimen. Attrition was defined as death or loss to follow-up (LTFU). LTFU was defined as "not presenting to an HIV care center for at least 180 days after the date of a last missed visit, without a notification of death or transfer". Kaplan-Meier curves were used to present attrition data, and mixed effects Cox regression models determined factors associated with attrition. The results compared were before and after the implementation of the "treat-all" strategy. A total of 15,762 PLWH were included in the study. Overall, retention in HIV care was 83% at twelve months and 77% after two years of follow-up. The risk of attrition increased with advanced HIV disease and the size of the HIV care center. Time to ART initiation greater than seven days after diagnosis and Cotrimoxazole prophylaxis was associated with a reduced risk of attrition. The implementation of the "treat-all" strategy modified the clinical characteristics of PLWH toward higher CD4 cell counts and a greater proportion of patients at WHO stages I and II at treatment initiation. Initiation of ART after the implementation of the 'treat all" strategy was associated with higher attrition (p<0.0001) and higher LTFU (p<0.0001). Attrition has remained high in recent years. The implementation of the "treat-all" strategy was associated with higher attrition and LTFU in our study. Interventions to improve early and ongoing commitment to care are needed, with specific attention to high-risk groups to improve ART coverage and limit HIV transmission.

Identifiants

pubmed: 36962315
doi: 10.1371/journal.pgph.0000259
pii: PGPH-D-21-00142
pmc: PMC10022330
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e0000259

Informations de copyright

Copyright: © 2022 Mayasi et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

No competing interests to declare.

Références

PLoS One. 2019 Jul 10;14(7):e0218555
pubmed: 31291273
PLoS One. 2020 Oct 19;15(10):e0240865
pubmed: 33075094
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
PLoS Med. 2017 Nov 28;14(11):e1002463
pubmed: 29182641
Ther Clin Risk Manag. 2020 Mar 04;16:169-180
pubmed: 32184609
Curr Opin Infect Dis. 2020 Feb;33(1):20-27
pubmed: 31743122
J Int AIDS Soc. 2018 Feb;21(2):
pubmed: 29479867
PLoS One. 2017 Sep 29;12(9):e0184879
pubmed: 28961253
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
BMC Public Health. 2020 Mar 14;20(1):328
pubmed: 32171279
J Int AIDS Soc. 2020 Nov;23(11):e25640
pubmed: 33247517
Trop Med Int Health. 2019 Jun;24(6):701-714
pubmed: 30938037
BMC Res Notes. 2018 May 10;11(1):287
pubmed: 29747698
PLoS One. 2020 Jan 7;15(1):e0222309
pubmed: 31910445
Clin Infect Dis. 2018 Jan 6;66(2):237-243
pubmed: 29020295
JAMA. 2018 Mar 20;319(11):1103-1112
pubmed: 29509839
Patient Prefer Adherence. 2019 Apr 03;13:475-490
pubmed: 31040651
AIDS. 2016 Nov 28;30(18):2855-2864
pubmed: 27603290
PLoS One. 2020 Jul 31;15(7):e0236801
pubmed: 32735566
AIDS Res Ther. 2015 Nov 12;12:37
pubmed: 26566390
PLoS One. 2015 Oct 16;10(10):e0140746
pubmed: 26473965
PLoS One. 2020 Jan 14;15(1):e0227572
pubmed: 31935240
AIDS Behav. 2018 Mar;22(3):752-764
pubmed: 27990582
PLoS One. 2020 Apr 7;15(4):e0217606
pubmed: 32255796
BMC Infect Dis. 2020 Jun 22;20(1):439
pubmed: 32571232
AIDS. 2021 Apr 1;35(5):841-843
pubmed: 33369905
AIDS. 2018 Jan 2;32(1):17-23
pubmed: 29112073
Public Health Action. 2020 Mar 21;10(1):33-37
pubmed: 32368522
Pan Afr Med J. 2020 Oct 29;37:198
pubmed: 33505567
BMC Public Health. 2019 Jan 28;19(1):117
pubmed: 30691425
BMJ Glob Health. 2017 Aug 6;2(3):e000325
pubmed: 29082011
J Acquir Immune Defic Syndr. 2015 May 1;69(1):98-108
pubmed: 25942461
J Int AIDS Soc. 2019 Feb;22(2):e25239
pubmed: 30734510
J Clin Epidemiol. 2020 Dec;128:83-92
pubmed: 32828836
Clin Infect Dis. 2018 Nov 13;67(11):1643-1652
pubmed: 29889240
BMJ Open. 2017 Aug 11;7(8):e016800
pubmed: 28801427
PLoS One. 2018 Jan 2;13(1):e0189770
pubmed: 29293523
Infect Dis Poverty. 2021 Mar 20;10(1):33
pubmed: 33743815
J Int AIDS Soc. 2020 Mar;23(3):e25458
pubmed: 32128964
AIDS Res Ther. 2016 Jul 26;13:27
pubmed: 27462361
PLoS One. 2020 Jan 24;15(1):e0227473
pubmed: 31978137
Infect Dis Poverty. 2016 Sep 05;5(1):85
pubmed: 27593965
J Int AIDS Soc. 2020 Sep;23(9):e25610
pubmed: 32949103
PLoS Med. 2019 May 31;16(5):e1002811
pubmed: 31150380
J Acquir Immune Defic Syndr. 2017 Sep 1;76(1):e15-e18
pubmed: 28394821
J Int AIDS Soc. 2019 Apr;22(4):e25279
pubmed: 30993854
AIDS. 2021 Feb 2;35(2):275-285
pubmed: 33048875
BMC Res Notes. 2019 Feb 28;12(1):111
pubmed: 30819236
Lancet HIV. 2017 May;4(5):e193-e194
pubmed: 28153471

Auteurs

Nadine Mayasi (N)

Department of Internal Medicine, Infectious and Tropical Diseases, University Clinics of Kinshasa, Kinshasa, Democratic Republic of the Congo [DRC].

Hippolyte Situakibanza (H)

Department of Internal Medicine, Infectious and Tropical Diseases, University Clinics of Kinshasa, Kinshasa, Democratic Republic of the Congo [DRC].

Marcel Mbula (M)

Department of Internal Medicine, Infectious and Tropical Diseases, University Clinics of Kinshasa, Kinshasa, Democratic Republic of the Congo [DRC].

Murielle Longokolo (M)

Department of Internal Medicine, Infectious and Tropical Diseases, University Clinics of Kinshasa, Kinshasa, Democratic Republic of the Congo [DRC].

Nathalie Maes (N)

Biostatistics and Medico-Economic Information Department, University Hospital of Liège, Liège, Belgium.

Ben Bepouka (B)

Department of Internal Medicine, Infectious and Tropical Diseases, University Clinics of Kinshasa, Kinshasa, Democratic Republic of the Congo [DRC].

Jérôme Odio Ossam (JO)

Department of Internal Medicine, Infectious and Tropical Diseases, University Clinics of Kinshasa, Kinshasa, Democratic Republic of the Congo [DRC].

Michel Moutschen (M)

Department of Internal Medicine and Infectious Diseases, Liège University Hospital, Liège, Belgium.
AIDS Reference Laboratory, University of Liège, Liège, Belgium.

Gilles Darcis (G)

Department of Internal Medicine and Infectious Diseases, Liège University Hospital, Liège, Belgium.

Classifications MeSH